Equities research analysts forecast that Stemline Therapeutics Inc (NASDAQ:STML) will announce ($0.41) earnings per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Stemline Therapeutics’ earnings. The lowest EPS estimate is ($0.53) and the highest is ($0.31). Stemline Therapeutics reported earnings of ($0.73) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 43.8%. The company is expected to report its next quarterly earnings report on Thursday, November 14th.
According to Zacks, analysts expect that Stemline Therapeutics will report full year earnings of ($1.99) per share for the current financial year, with EPS estimates ranging from ($2.32) to ($1.71). For the next year, analysts expect that the firm will report earnings of ($0.11) per share, with EPS estimates ranging from ($1.22) to $1.68. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Stemline Therapeutics.
Stemline Therapeutics (NASDAQ:STML) last issued its earnings results on Friday, August 2nd. The biopharmaceutical company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.05. The company had revenue of $13.01 million during the quarter, compared to the consensus estimate of $8.84 million.
In related news, CEO Ivan Bergstein sold 10,822 shares of the firm’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $15.49, for a total transaction of $167,632.78. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Kenneth Hoberman sold 25,817 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $14.27, for a total value of $368,408.59. The disclosure for this sale can be found here. In the last ninety days, insiders sold 149,177 shares of company stock worth $2,236,377. Insiders own 13.10% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc raised its holdings in shares of Stemline Therapeutics by 27.1% during the 4th quarter. Legal & General Group Plc now owns 5,249 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 1,120 shares in the last quarter. Allianz Asset Management GmbH raised its holdings in shares of Stemline Therapeutics by 7.2% during the 2nd quarter. Allianz Asset Management GmbH now owns 21,309 shares of the biopharmaceutical company’s stock valued at $326,000 after buying an additional 1,427 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Stemline Therapeutics by 18.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 11,004 shares of the biopharmaceutical company’s stock valued at $166,000 after buying an additional 1,715 shares in the last quarter. Knott David M raised its holdings in shares of Stemline Therapeutics by 1.3% during the 1st quarter. Knott David M now owns 157,795 shares of the biopharmaceutical company’s stock valued at $2,028,000 after buying an additional 2,000 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Stemline Therapeutics during the 1st quarter valued at about $36,000. 78.78% of the stock is currently owned by institutional investors.
NASDAQ STML traded up $0.26 during trading hours on Monday, hitting $15.55. The company had a trading volume of 626,600 shares, compared to its average volume of 602,276. Stemline Therapeutics has a 52 week low of $7.82 and a 52 week high of $18.22. The company’s 50 day moving average is $14.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.71 and a quick ratio of 5.03. The company has a market capitalization of $725.27 million, a price-to-earnings ratio of -5.20 and a beta of 1.29.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.
Read More: Cash Asset Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.